Tiziana Life Sciences Ltd (TLSA) Form 6-K — Nov 5, 2026
Tiziana Life Sciences announced it will host a KOL investor call on November 9, 2026 to discuss positive topline results from its Phase 2a INFORM-MS trial of intranasal foralumab in non-active secondary progressive multiple sclerosis. The trial met its primary endpoint, with the 50μg dose showing a statistically significant reduction in microglial activation on TSPO PET imaging (p=0.0168), and both dose arms showed clinically meaningful, statistically significant fatigue improvements (MFIS) after only 12 weeks versus minimal placebo change. All 48 participants completed treatment with no study-drug-related serious adverse events.
Key figures
- Primary Endpoint PValue
- p=0.0168
- Trial
- Phase 2a INFORM-MS in non-active secondary progressive MS (na-SPMS)
- Mfis 50ug p
- 0.035
- Doses tested
- ["50μg","100μg"]
- Mfis 100ug p
- 0.040
- Participants
- 48
- Primary endpoint
- Reduction in microglial activation on TSPO PET imaging, 50μg arm
- Treatment duration weeks
- 12
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.